Carisma Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Mar 28

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry

You may think that with a price-to-sales (or "P/S") ratio of 0.7x Carisma Therapeutics, Inc. ( NASDAQ:CARM ) is...

Analiz Makalesi • Dec 06

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares have had a horrible month, losing 28% after a relatively good period...

Analiz Makalesi • Sep 02

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • May 12

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) just released its latest quarterly report and things are not looking great...

Analiz Makalesi • Apr 19

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

The Carisma Therapeutics, Inc. ( NASDAQ:CARM ) share price has fared very poorly over the last month, falling by a...

Analiz Makalesi • Mar 26

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jan 21

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shareholders won't be pleased to see that the share price has had a very...

Analiz Makalesi • Dec 07

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

To the annoyance of some shareholders, Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares are down a considerable 27% in...

Analiz Makalesi • Nov 12

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

The analysts covering Carisma Therapeutics, Inc. ( NASDAQ:CARM ) delivered a dose of negativity to shareholders today...

Analiz Makalesi • Oct 05

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Jun 15

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Carisma Therapeutics CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Saar Gill	Co-Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Sanford Zweifach	Independent Chairman of the Board	3.3yrs	US$143.23k	0.00099% $ 2.4
Hyam Levitsky	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Carl June	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nina Bhardwaj	Member of Scientific Advisory Board	6yrs	Veri yok	Veri yok
Steven Kelly	Director	3.3yrs	US$1.72m	0% $ 0
Scott L. Friedman	Member of Scientific Advisory Board	1.9yrs	Veri yok	Veri yok
Marella Thorell	Independent Director	2.1yrs	US$81.48k	0% $ 0
Lisa Coussens	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Prasad Adusumilli	Member of Scientific Advisory Board	6yrs	Veri yok	Veri yok
Sohanya Cheng	Independent Director	1.8yrs	US$39.29k	0% $ 0
Lin Guey	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/17 08:05
Gün Sonu Hisse Fiyatı	2026/07/15 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Carisma Therapeutics, Inc. 5 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Naureen Quibria	Capital One Securities, Inc.

Carisma Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Carisma Therapeutics, Inc. Announces Leaving of Richard Morris as Chief Financial Officer, Effective December 31, 2024

Carisma Therapeutics Announces Changes to Its Board of Directors

Carisma Therapeutics, Inc. Announces Appointments of Its Scientific Advisory Board

Carisma Therapeutics, Inc. Announces Board Changes

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Recent updates

Carisma Therapeutics Files Form 15

Carisma Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Carisma Therapeutics Notifies Nasdaq of the Company’s Intention to File a Form 25 with the Sec on or About December 10, 2025 to Effect the Formal Delisting of the Common Stock

Carisma Therapeutics, Inc.(NasdaqCM:CARM) dropped from S&P TMI Index

Carisma Therapeutics Inc Receives a Delisting Determination Letter from the Nasdaq Stock Market

New major risk - Market cap size

Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.27 loss in 2Q 2024)

New major risk - Revenue and earnings growth

Carisma Therapeutics, Inc. Provides Update on Nasdaq Non-Compliance

OrthoCellix, Inc. entered into an agreement to Carisma Therapeutics, Inc. (NasdaqCM:CARM) in a reverse merger transaction.

High number of new and inexperienced directors

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry

Carisma Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Carisma Therapeutics, Inc. Announces Leaving of Richard Morris as Chief Financial Officer, Effective December 31, 2024

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Carisma Therapeutics Inc. Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics, Inc. Announces to Present New Data on Anti-GPC3 in Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics Announces Changes to Its Board of Directors

Carisma Therapeutics Receives Written Notice from Nasdaq Regarding Non- Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5450(b)(2)(A)

Carisma Therapeutics, Inc.(NasdaqGM:CARM) dropped from S&P Global BMI Index

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Carisma Therapeutics, Inc. Announces Appointments of Its Scientific Advisory Board

Carisma Therapeutics, Inc.(NasdaqGM:CARM) dropped from Russell 3000 Index

Carisma Therapeutics, Inc. Announces Board Changes

Carisma Therapeutics, Inc. Grants FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

New major risk - Revenue and earnings growth

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

First quarter 2024 earnings released: US$0.46 loss per share (vs US$1.93 loss in 1Q 2023)

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Carisma Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Price target decreased by 12% to US$8.40

Consensus revenue estimates increase by 107%

Price target decreased by 7.7% to US$9.00

Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

New minor risk - Market cap size

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Consensus revenue estimates increase by 41%, EPS downgraded

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

New minor risk - Market cap size

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors

New major risk - Share price stability

Carisma Therapeutics Inc. Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources